Histone Deacetylase Inhibitors (HDAC) Inhibitors Market, 2016 - 2026 - Currently 90 Molecules Under development - Research and Markets

News provided by

Sep 07, 2016, 01:10 ET

DUBLIN, September 7, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "HDAC Inhibitors Market, 2016 - 2026" report to their offering.

The HDAC Inhibitors Market, 2016-2026 report was commissioned to examine the current landscape and the future outlook of the growing pipeline of products in this area. HDACs have been studied in cellular processes such as apoptosis, autophagy, metabolism, DNA damage repair, cell cycle control and senescence.

The study provides a detailed market forecast and opportunity analysis for the time period 2016-2026. The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III and phase II). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios. Our opinions and insights, presented in this study were influenced by several discussions we conducted with experts in this area. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Currently, the HDAC inhibitors' pipeline comprises of over 90 molecules under development. It is worth highlighting that over the last few years, the focus has shifted from pan-HDAC to class-specific HDAC inhibitors. Additionally, the research activity, with respect to the number of publications, has been highly promising. With an intense research framework, there have been over 9500 papers published in the last 10 years (as captured in PubMed). Further, increasing popularity on social media validates the growing interest in this field. The analysis conducted from 2009 to 2015 demonstrates a Compound Annual Growth Rate (CAGR) of 33% in the tweets registered on Twitter. Similar trends have been observed on Facebook.

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market.

This was done by analyzing:

The HDAC inhibitor pipeline (marketed, clinical and preclinical drugs) in terms of phase of development, HDAC class specificity and the evolving therapeutic areas / target indications.
The likely adoption of the HDAC inhibitors by understanding the competition posed by the current treatment regime in the coming few years.
The emerging trends and the popularity of HDAC inhibitors on social media such as Twitter and Facebook over the last few years.
The research activity in this field in terms of the focus of the publications / research articles granted across the globe in the last two years.

Key Topics Covered:

1. Preface
2. Executive Summary
3. Introduction
4. HDAC Inhibitors: Market Landscape
5. Drug Profiles: Marketed And Late-Stage HDAC Inhibitors
6. Key Insights: Therapeutic Area, Class Specificity, Clinical Endpoints
7. Market Forecast And Opportunity Analysis
8. Publication Analysis
9. Social Media: Emerging Trends
10. Conclusion
11. Interview Transcripts
12. Appendix 1: Tabulated Data
13. Appendix 2: List Of Companies And Organizations

Companies Mentioned - Partial List

AbbVie
AcelRx pharma
Acorda Therapeutics
Actavis
Acura Pharma
Acorda Therapeutics
Altus formulations
Alkermes
Algiax Pharmaceuticals
Amorsa Therapeutics
AnGes
AstraZeneca
Balerna
Biogen
BioDelivery Sciences International Inc
Biopharma
Cara Therapeutics
Catalent
Charleston
Celltech
Collegium Pharma
Convergence
Columbia Labs
Convatech
Daiichi Sankyo
Daewoong
Depomed
Durect
Egalet
Eli Lilly
Elite Pharma
Endo
Ensyce Bioscience
EpiCept
Flamel Technologies
Flexion Therapeutics
Forest
Glenmark
Grunenthal
GlaxoSmithKline
GW Pharma
Immune Pharmaceuticals
Impax Pharmaceuticals
Inspirion
Intelli Pharmaceutics
IRX Therapeutics
Johnson and Johnson
KemPharm
Kineta
Kunwha Pharmaceutical
Medallion Therapeutics
Mallinckrodt
Nektar
Novartis
Noven
Orbis Biosciences
Orexo
Otsuka
Pain Therapeutics
Pfizer
ProPharma
Purdue
Recro pharma
Relmada Therapeutics
Reckitt Benckiser pharmaceutical
Signature Therapeutics
Spinifex pharma
SPR Therapeutics
Strativa
Teikoku
Teva
Tesa Labtec GmpH
Trevena Inc
Tris Pharma
Valeant
ViroMed
Wooddiff Lake
Xenon Pharma
XenoPort

For more information about this report visit http://www.researchandmarkets.com/research/6zk8cq/hdac_inhibitors

Also Available

World Histone Deacetylase Inhibitors Market - Opportunities and Forecasts, 2014 - 2022

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets